Epidermal growth factor receptor in relation to tumor development: EGFR-targeted anticancer therapy

Research output: Contribution to journalShort survey

62 Citations (Scopus)

Abstract

The discovery that signaling by the epidermal growth factor receptor (EGFR) plays a key role in tumorigenesis prompted efforts to target this receptor in anticancer therapy. Two different types of EGFR-targeted therapeutic agents were subsequently developed: mAbs, such as cetuximab and panitumumab, which target the extracellular domain of the receptor, thereby inhibiting ligand-dependent EGFR signal transduction; and small-molecule tyrosine kinase inhibitors, such as gefitinib and erlotinib, which target the intracellular tyrosine kinase domain of the EGFR. Furthermore, recent clinical and laboratory studies have identified molecular markers that have the potential to improve the clinical effectiveness of EGFR-targeted therapies. This minireview summarizes the emerging role of molecular profiling in guiding the clinical use of anti-EGFR therapeutic agents.

Original languageEnglish
Pages (from-to)309-315
Number of pages7
JournalFEBS Journal
Volume277
Issue number2
DOIs
Publication statusPublished - Jan 1 2010
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Biochemistry
  • Molecular Biology
  • Cell Biology

Fingerprint Dive into the research topics of 'Epidermal growth factor receptor in relation to tumor development: EGFR-targeted anticancer therapy'. Together they form a unique fingerprint.

  • Cite this